BPC-157 Side Effects: Heart, Drug Tests, Long-Term Unknowns

Key takeaways

• There is no human safety study of BPC-157 beyond three uncontrolled pilots from one Florida clinic: two reported no adverse events in 14 people, and a knee-pain chart review did not report on them. Long-term effects in people have never been studied.
• Animal toxicology in four species found no serious toxicity, mild local irritation, no genetic or embryo-fetal toxicity, and a reversible creatinine drop in dogs at the highest dose.
• The theoretical risks follow from the mechanism: new blood vessel growth (a tumor concern), nitric oxide effects (blood pressure), and immune reactions, which FDA's reviewers raised in July 2026.
• The heart claims come from rat studies by the laboratory that discovered the peptide; the only human cardiac data are blood tests in two people after single infusions.
• WADA's 2026 Prohibited List names BPC-157 under S0, banned at all times, and anti-doping laboratories detect it in urine at 0.1 ng/mL. Federally regulated workplace tests cover five drug classes and do not include it.

BPC-157 side effects in humans are essentially unknown: no study has been designed to find them, and the whole human record is three uncontrolled pilot studies with about 30 people. This page sets out what those pilots and the animal toxicology show, the theoretical risks, the heart and drug-test questions, and when to stop. It is part of our peptide side effects guide; for a peptide with real side-effect data, compare sermorelin side effects, and for the evidence and legal status in full, read the BPC-157 profile.

BPC-157 safety at a glance

What the three human pilots reported

Every published human study of BPC-157 comes from one private clinic in Florida, and none had a control group.

• Intravenous safety, 2025. A 58-year-old man and a 68-year-old woman, both previous users, received 10 mg infused over an hour on day one and 20 mg on day two. Blood markers of the heart, liver, kidneys, thyroid and glucose did not change, and no side effects were reported (Lee 2025).
• Interstitial cystitis, 2024. Twelve women aged 39 to 76 had 10 mg injected around the inflamed bladder wall during cystoscopy. No one dropped out and no adverse events were reported (Lee 2024).
• Knee pain, 2021. A retrospective chart review of 17 patients given an intra-articular injection, 16 of whom were phoned 6 to 12 months later about their pain. The abstract does not mention adverse events at all (Lee 2021).

That is about 30 people, most treated once, none followed on repeated dosing. Fourteen people can only rule out very common side effects; anything affecting fewer than about one person in five could easily be missed. People who inject research vials describe injection-site pain, nausea, dizziness, fatigue and headache, but none of it has been collected systematically or can be pinned on BPC-157 rather than on something else in the vial.

Animal toxicology

The only formal safety program is a Chinese preclinical study in mice, rats, rabbits and dogs. Single doses produced no test-related effects. Repeated doses were well tolerated in dogs, except for a fall in creatinine at 2 mg/kg that reversed within two weeks of stopping. Local irritation was mild, and there was no genetic toxicity and no harm to embryos or fetuses (Xu 2020). Reassuring as far as it goes, but animal toxicology screens for obvious organ damage; it cannot answer the questions about tumors, immune reactions and years of human use.

The theoretical risks

Blood vessels and tumors. BPC-157's best-documented action, shown by a Taiwanese group independent of its discoverers, is angiogenesis: it increased vessel density in chick embryo membranes and endothelial cell cultures, sped blood-flow recovery in rats with blocked leg arteries, and raised expression of VEGF receptor 2 and its Akt-eNOS signaling (Hsieh 2017). That is the basis of the healing claims and of the tumor concern, because tumors need new vessels to grow and spread. Nobody has studied BPC-157 in people with cancer, diagnosed or not; the BPC-157 profile covers the debate between its discoverers, who report anti-tumor effects in animals, and unconvinced outside reviewers.

Nitric oxide and blood pressure. In rats, BPC-157 generated nitric oxide in stomach tissue, left normal blood pressure unchanged, blunted the rise caused by the nitric oxide blocker L-NAME and prevented the fall caused by L-arginine (Sikiric 1997). Nitric oxide is the main regulator of vessel tone. We found no study of BPC-157 taken with blood pressure medicines, or with nitrates and erectile dysfunction drugs, which act through the same nitric oxide system.

Immune reactions. Any injected peptide can provoke antibodies, and impurities and aggregates make it more likely. When FDA's reviewers assessed BPC-157 and six other peptides in July 2026, the concerns they cited across the group were insufficient human data, uncertainty about the identity and composition of what is sold, and immunogenicity (Kelley Drye 2026).

BPC-157 and the heart

The heart claims on sales pages come from rats, almost all from the Zagreb laboratory that discovered BPC-157. Beyond the blood pressure work above, the group gave rats a large dose of isoprenaline, a drug that causes heart-muscle injury resembling a heart attack, and reported that BPC-157 at 10 ng/kg or 10 mcg/kg lowered heart-damage markers (CK, CK-MB, LDH and troponin), prevented ischemic ECG changes and preserved pumping function on echocardiography (Barisic 2022). These are acute injuries in rats treated around the time of injury, from one laboratory; the BPC-157 profile explains why that pattern calls for caution.

In people, the cardiac evidence is two adults whose heart-related blood tests did not change after single infusions (Lee 2025). Nobody has measured blood pressure, heart rhythm or clotting in people injecting BPC-157 for weeks. In humans, what it does to the heart is unknown, and anyone with heart disease, high blood pressure or a clotting history should treat it as an unknown rather than a treatment.

Drug tests: sport versus the workplace

Anti-doping tests. BPC-157 is prohibited at all times in tested sport. WADA's 2026 Prohibited List names it as an example under S0, the class for substances not approved for human therapeutic use (WADA 2026), and USADA treats it as a Specified Substance in that class; in September 2025 it announced a four-year sanction for a triathlete who used and possessed BPC-157 and TB-500 (USADA 2025). After BPC-157 turned up in confiscated vials, a Salt Lake City anti-doping laboratory validated a urine method with a detection limit of 0.1 ng/mL and identified a stable metabolite that improves specificity (Cox 2017). We found no published human excretion study, so nobody can say how many days after a dose a test stays positive. The Wolverine stack page covers the combination with TB-500, which WADA names under S2.

Workplace tests. Federally regulated workplace tests, such as those for transportation workers, are limited by rule to five drug classes: marijuana, cocaine, amphetamines, opioids and PCP, and laboratories may not test those specimens for anything else (49 CFR 40.82). As general knowledge rather than a sourced finding: private employers' expanded panels add classes such as benzodiazepines, barbiturates and methadone, and we are not aware of any standard employment panel that includes BPC-157, which takes the specialized mass spectrometry anti-doping laboratories use. Two caveats: a research vial could contain something other than BPC-157, and sports organizations outside the WADA system run their own testing programs with their own lists.

Risks from the research-grade product

As of October 2026 no US pharmacy may compound BPC-157, so every vial, capsule and spray on the market is a research product with no verified identity, potency or sterility; the legal tracker explains why a prescription does not change that. Laboratory tests of comparable online peptides found purity as low as 5 percent, heavy metals and endotoxin, as our peptide side effects guide describes. A fever after a dose is more likely to come from the vial than from the peptide.

When to stop and seek care

Stop and get care the same day for:

• fever, chills or shaking within hours of an injection (possible endotoxin or infection);
• spreading redness, warmth, swelling or pus at the injection site;
• hives, swelling of the face or lips, or wheezing (call emergency services if breathing is affected);
• chest pain, fainting, palpitations or a marked change in blood pressure;
• any new diagnosis of cancer, or a pregnancy.

Do not use BPC-157 at all if you have an active or past cancer, are pregnant, trying to conceive or breastfeeding, have uncontrolled blood pressure, heart disease or a clotting disorder, or compete in tested sport. If you react, keep the vial; it is the only evidence of what you took. Normal site reactions are described in how to inject peptides.

Bottom line

BPC-157 has a clean animal toxicology record and almost no human safety data: three uncontrolled pilots, about 30 people, no repeated dosing, no long-term follow-up. Its theoretical risks follow from what it does in rats, growing blood vessels and acting on nitric oxide, and its heart benefits exist only in rats. In tested sport it is banned by name and detectable; on an ordinary workplace panel it is not looked for. The most concrete risk is a research vial that nobody has checked.

Frequently asked questions

+−What are the side effects of BPC-157?

No human study has been designed to find them. Two small pilot studies, 2 people given intravenous infusions and 12 women given a single bladder-wall injection, reported no adverse events, and a third, a knee-pain chart review, did not report on them. Animal toxicology in four species found no serious toxicity. People who inject research vials describe injection-site pain, nausea, dizziness, fatigue and headache, but none of that has been collected systematically. The theoretical risks, blood vessel growth, blood pressure effects and immune reactions, have never been tested in people.

+−What does BPC-157 do to the heart?

In rats, the Zagreb laboratory that discovered BPC-157 reports protective effects: it blunted drug-induced rises and falls in blood pressure without changing normal pressure, and in a rat heart-attack model it lowered heart-damage markers and preserved pumping function. In people, the only cardiac data are blood tests in two adults after single intravenous infusions, which did not change. Nobody has measured blood pressure, heart rhythm or clotting in people taking it repeatedly, so any heart claim, good or bad, is untested in humans.

+−Does BPC-157 show up on a drug test?

On an anti-doping test, yes, it can: laboratories have a validated urine method that detects BPC-157 at 0.1 ng/mL, and WADA's 2026 Prohibited List names it under S0, prohibited at all times. On a routine workplace test, almost certainly not: federally regulated tests are limited by rule to five drug classes (marijuana, cocaine, amphetamines, opioids and PCP), and as far as we know no standard employer panel includes BPC-157, which needs specialized mass spectrometry to detect.

+−Is BPC-157 safe long term?

Nobody knows. No person has been followed while taking BPC-157 repeatedly, the longest human follow-up is a phone survey 6 to 12 months after a single knee injection that did not report adverse events, and the animal toxicology program measured short-term effects. Long-term safety in humans is simply unstudied.

+−Can BPC-157 cause cancer?

There is no evidence that it does and no study that could show it either way. The concern is theoretical but rooted in its best-established mechanism: BPC-157 grows new blood vessels through the VEGFR2 pathway, and tumors depend on new vessels to grow and spread. Its discoverers report anti-tumor effects in animals; outside reviewers remain cautious. Anyone with a current or past cancer should treat it as an unknown risk.

+−Is BPC-157 banned in sports?

Yes. WADA's 2026 Prohibited List names BPC-157 as an example of S0, non-approved substances, prohibited at all times in and out of competition, and USADA classes it as a Specified Substance in that class. In September 2025 USADA announced a four-year sanction for a triathlete who used and possessed BPC-157 and TB-500.

+−What are the negative side effects of peptide injections?

For any injected peptide: redness, itching or lumps at the site, infection from non-sterile technique or product, allergic reactions, and endotoxin, a bacterial residue that causes fever, chills and low blood pressure within hours. For research vials such as BPC-157, add unverified content and dose. Our peptide side effects guide covers each risk by compound.

Sources

1. StudyLee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med 2021;27(4):8-13. (2021)
2. StudyLee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024;30(10):12-17. (2024)
3. StudyLee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025;31(5):20-24. (2025)
4. StudyXu C et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol 2020;114:104665. (2020)
5. StudyHsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95:323-33. (2017)
6. StudySikiric P et al. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol 1997;332:23-33. (1997)
7. StudyBarisic I et al. Stable gastric pentadecapeptide BPC 157 may counteract myocardial infarction induced by isoprenaline in rats. Biomedicines 2022;10:265. (2022)
8. StudyCox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal 2017;9:1490-8. (2017)
9. RegulatoryWorld Anti-Doping Agency. The 2026 Prohibited List (in force January 1, 2026): S0, non-approved substances, prohibited at all times, names BPC-157 among its examples. (2026)
10. NewsUS Anti-Doping Agency. Sanction announcement for a triathlete for use and possession of BPC-157 and TB-500 (BPC-157 classified as a Specified Substance in the class of Non-Approved Substances; four-year ineligibility). September 17, 2025. (2025)
11. NewsKelley Drye. FDA advisory committee recommends several peptides for compounding despite staff opposition: what stakeholders need to know (FDA staff cited insufficient human data, uncertain identity and immunogenicity). July 30, 2026. (2026)
12. Regulatory49 CFR 40.82, What drugs do laboratories test for? (DOT workplace drug testing: five drug classes; laboratories must not test DOT specimens for any other drugs). Legal Information Institute, Cornell Law School. (2023)